Show simple item record

dc.creatorLukačišinová, Anna
dc.creatorReissigová, Jindra
dc.creatorOrtner-Hadžiabdić, Maja
dc.creatorBrkić, Jovana
dc.creatorOkuyan, Betul
dc.creatorVolmer, Daisy
dc.creatorTadić, Ivana
dc.creatorModamio, Pilar
dc.creatorMariño, Eduardo
dc.creatorTachkov, Konstantine
dc.creatorLiperotti, Rosa
dc.creatorOnder, Graziano
dc.creatorFinne-Soveri, Harriet
dc.creatorvan Hout, Hein
dc.creatorHoward, Elizabeth P.
dc.creatorFialová, Daniela
dc.date.accessioned2024-03-20T08:55:27Z
dc.date.available2024-03-20T08:55:27Z
dc.date.issued2024
dc.identifier.issn1471-2318
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/5563
dc.description.abstractBackground: The use of benzodiazepines (BZDs) in older population is often accompanied by drug-related complications. Inappropriate BZD use significantly alters older adults’ clinical and functional status. This study compares the prevalence, prescribing patterns and factors associated with BZD use in community-dwelling older patients in 7 European countries. Methods: International, cross-sectional study was conducted in community-dwelling older adults (65 +) in the Czech Republic, Serbia, Estonia, Bulgaria, Croatia, Turkey, and Spain between Feb2019 and Mar2020. Structured and standardized questionnaire based on interRAI assessment scales was applied. Logistic regression was used to evaluate factors associated with BZD use. Results: Out of 2,865 older patients (mean age 73.2 years ± 6.8, 61.2% women) 14.9% were BZD users. The highest prevalence of BZD use was identified in Croatia (35.5%), Spain (33.5%) and Serbia (31.3%). The most frequently prescribed BZDs were diazepam (27.9% of 426 BZD users), alprazolam (23.7%), bromazepam (22.8%) and lorazepam (16.7%). Independent factors associated with BZD use were female gender (OR 1.58, 95%CI 1.19–2.10), hyperpolypharmacy (OR 1.97, 95%CI 1.22–3.16), anxiety (OR 4.26, 95%CI 2.86–6.38), sleeping problems (OR 4.47, 95%CI 3.38–5.92), depression (OR 1.95, 95%CI 1.29–2.95), repetitive anxious complaints (OR 1.77, 95%CI 1.29–2.42), problems with syncope (OR 1.78, 95%CI 1.03–3.06), and loss of appetite (OR 0.60, 95%CI 0.38–0.94). In comparison to Croatia, residing in other countries was associated with lower odds of BZD use (ORs varied from 0.49 (95%CI 0.32–0.75) in Spain to 0.01 (95%CI 0.00–0.03) in Turkey), excluding Serbia (OR 1.11, 95%CI 0.79–1.56). Conclusions: Despite well-known negative effects, BZDs are still frequently prescribed in older outpatient population in European countries. Principles of safer geriatric prescribing and effective deprescribing strategies should be individually applied in older BZD users.
dc.publisherBioMed Central Ltd
dc.relationThe European Union (EU) funded project InoMed, reg. No: CZ.02.1.01/0.0/0.0/18_069/0010 046 (2019–2022)
dc.relationThe European Union’s Horizon 2020
dc.relationInnovation programme under the Marie Skłodowska‑Curie grant agreement No. 764632 (EuroAgeism H2020 ESR7 project)
dc.relationThe European Union’s Horizon 2020 research and innovation programme under grant agreement No 965341
dc.relationThe I‑CARE4 OLD Horizon 2020 project.
dc.relationThe EuroAgeism H2020 ESR7 project
dc.relationThe grant agreement of the Marie Skłodowska‑Curie Foundation number MSCF‑ITN‑764632
dc.relationThe research group “Aging, polypharmacotherapy and changes in therapeutic value of drugs in the aged” (chair: Assoc. Prof. Daniela Fialova, PharmD., Ph.D.)
dc.relationThe scientific program Cooperatio KSKF1 of the Faculty of Pharmacy, Charles Uni‑ versity in Hradec Kralove
dc.relationThe project START / MED / 093 EN.02.2.69 / 0.0 / 0.0 / 19_073 / 0016935 and SVV program 260 665, and the project NETPHARM (New Technologies for Translational Research in Pharmaceutical Sciences
dc.relationProject ID: CZ.02.01.01/00/22_008/0004607)
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/share-your-work/public-domain/cc0/
dc.sourceBMC Geriatrics
dc.subjectEurope
dc.subjectBenzodiazepines
dc.subjectCommunity-dwelling older adults
dc.subjectGeriatric dosing
dc.subjectGeriatric length of therapy
dc.titlePrevalence, country-specific prescribing patterns and determinants of benzodiazepine use in community-residing older adults in 7 European countries
dc.typearticle
dc.rights.licenseCC0
dc.citation.volume24
dc.citation.issue1
dc.identifier.wos001180560000003
dc.identifier.doi10.1186/s12877-024-04742-7
dc.identifier.pmid38454372
dc.identifier.scopus2-s2.0-85187196137
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs/bitstream/id/15684/Prevalence,_country-specific_prescribing_pub_2024.pdf
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record